Who
Keith A. Goldan
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Syndax Pharmaceuticals; Director, Abeona Therapeutics; Chief Financial Officer, OptiNose; SVP and CFO, Fibrocell Science; CFO and SVP, Nupathe.
In numbers
- Trades disclosed
- 69
- Buys
- 4
- Sells
- 11
- Bought
- $47K
- Sold
- $381K
- Companies
- 5
- Companies where not an officer
- 1
- First trade
- 11 Aug 2010
- Last trade
- 1 Jun 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 2 Jun 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $22K1,177 at $18.99 | filing |
| 1 Jun 2026filed 2 Jun 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $22K1,177 at $18.99 | filing |
| 1 Apr 2026filed 7 Apr 2026 | ABEO Abeona TherapeuticsBiotechnology | SEC FORM 4 Code A | —32,751 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | ABEO Abeona TherapeuticsBiotechnology | SEC FORM 4 Code A | —32,751 at $0.00 | filing |
| 9 Feb 2026filed 10 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $72K3,410 at $21.03 | filing |
| 9 Feb 2026filed 10 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $72K3,410 at $21.03 | filing |
| 6 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $43K2,082 at $20.62 | filing |
| 6 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $43K2,082 at $20.62 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —21,500 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —30,750 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $2.4M118,000 at $20.43 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $2.4M118,000 at $20.43 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —21,500 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —30,750 at $0.00 | filing |
| 30 Jan 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code J | $10K1,219 at $8.48 | filing |
| 30 Jan 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code J | $10K1,219 at $8.48 | filing |
| 1 Dec 2025filed 1 Dec 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —1,224 at $0.00 | filing |
| 31 Jul 2025filed 7 Aug 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code J | $10K1,226 at $8.43 | filing |
| 16 Jul 2025filed 18 Jul 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $12K1,296 at $9.29 | filing |
| 19 May 2025filed 19 May 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Bought | —3,000 | filing |
News
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down – Here's WhySNDX · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name Keith A. Goldan; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.